---
title: "Confounded Exposure Response"
output:
  slidy_presentation:
    fig_width: 9
    fig_height: 5
    font_adjustment: 3
    transition: none
    css: slidystyles.css
    footer: metrumrg &copy 2021
    mathjax: local
    self_contained: false
#bibliography: alpha.bib
#nocite: | 
#    @2795, @2192, @3684
---


```{r,echo=FALSE,message=FALSE}
knitr::opts_chunk$set(comment='.',fig.align=TRUE,message=FALSE,warning=FALSE)
library(tidyverse)
library(stringr)
library(haven)
library(survival)
library(GGally)
library(binom)
library(texreg)
set.seed(314159)

expit <- function(x) 1 / (1+exp(-x))
``` 

# Outline

* Trastuzumab in mGC
* What is confounding?
* Why is it a problem?
* Thinking causally
* What are some solutions?

# Important to understand exposure-response relationships

A key componant of decision-making:

* Sponsors: Dose-selection for Phase 3
* Regulators: "Optimizing" benefit-risk in a population
* Physicians: "Optimizing" benefit-risk for a patient

# In some development programs, only one dose is studied extensively

* Common practice in oncology
   * Find MTD -> run expansion cohort (1b/2) -> Phase 3
* Not uncommon in other disease areas
   * Vedolizumab in UC
   * __other examples__
   
# With biologics this can cause a problem

* Apparent exposure-response not confirmed in subesquent studies
* __Give examples from Dai__


# ToGA: Trastuzumab in metastatic gastric cancer

:::: {style="display: grid; grid-template-columns: 50% 50%; grid-column-gap: 10px;"}

::: {}
ToGA trial demonstrated benefit of trastuzumab in mGC, but possibly less effective in patients with low exposure

* Phase 3, randomized, OL study
* Fluoropyrimidine and cisplatin (FC) vs. trastuzumab + FC (T+FC)
* Trastuzumab dosed with 'standard' regimen
* Overall effect (top panel @Bang2010-lp)
* By $C{\text{min},1}$ quartile (bottom panel @Yang2013-tr)

Led to a trial designed to compare a standard and high-dose trastuzumab regimens.

:::

::: {}


```{r, echo=FALSE, out.width="60%", fig.cap="Overall OS effect"}
knitr::include_graphics("graphics/ToGA-overall.png")
```


```{r, echo=FALSE, out.width="60%", fig.cap="OS by exposure quartile"}
knitr::include_graphics("graphics/Yang-Figure1A.png")
```

:::

::::


# The analysis of ToGA led to the HELOISE trial

:::: {style="display: grid; grid-template-columns: 50% 50%; grid-column-gap: 10px;"}

::: {}
HELOISE trial demonstrated no additional benefit of high dose trastuzumab in mGC

* Phase 3b, randomized, OL study in 1L mGC
* Trastuzumab standard regimen vs high-dose regimen
* Both regimens included cisplatin + capecitabine
* Overall effect (top panel @Shah2017-yo)
* By $C{\text{min},1}$ quartile (bottom panel @Shah2017-yo)


:::

::: {}


```{r, echo=FALSE, out.width="60%", fig.cap=""}
knitr::include_graphics("graphics/HELOISE-overall.png")
```


```{r, echo=FALSE, out.width="60%", fig.cap=""}
knitr::include_graphics("graphics/HELOISE-subset.png")
```

:::

::::


# What happened?

* The apparent exposure-response in the ToGA trial was an artefact of `counfounding`

* Subsequent analyses (@Yang2013-tr) confirmed the lack of an exposure-response relationship in the ToGA study.


# This observation is common with large molecules which are studied at one dose

<< give other examples: T-DM1, tremi, vedo >>

* Why is this a particular problem for large molecules?
* Why is that compounded when studying a single dose regimen?


# What is confounding?

* Our primary interest is in the _causal_ effect of exposure on an outcome.
   * _If we change exposure, how does the response change?_
* `Confounding` is a bias in the estimate of the causal effect.
* Occurs when there is a `common cause` of exposure and the outcome.

```{example}
Exposure-response confounding occurs when there is a common cause of exposure and the outcome of interest.
```

# How does a common cause introduce bias?

* Suppose there is no relationship between exposure (E) and the outcome (O)
* There is one common cause (A) of both
* We can represent this in a _directed acyclic graph_ (DAG)

```{r,engine='tikz',echo=FALSE}
\begin{tikzpicture}
\tikzset{every node}=[font=\sffamily]
\node (v0) at (0,0) {E};
\node (v1) at (6,0)  {O};
\node[align=center] (v2) at (0,-2)  {A} ;
\draw [->] (v2) edge (v1);
\draw [->] (v2) edge (v0);
\end{tikzpicture}
```

* This induces a relationship between exposure and outcome
    * Yet, there is no causal effect of exposure on the outcome
    * _Association is not causation_

# Simulated data

```{r}
simulated_data <- tibble(
  A = rnorm(100),
  E = exp(-2 + A + rnorm(100,sd=0.2)),
  O = 10 + A + rnorm(100)  # No direct link between E and O
)
```

```{r, echo=FALSE}
simulated_data %>% 
  ggplot(aes(x=E, y=O)) + 
  geom_point() +
  geom_smooth(method='gam', mapping=aes(color='Association')) +
  geom_hline(yintercept = 10, color='red') +
  theme_bw() +
  labs(x='Exposure (E)', y="Outcome (O)") +
  scale_color_manual(name="Effect", values=c('Association'="blue",'Causal'="red"))
```

# The same type of problem can occur when there is an E-R relationship


```{r,engine='tikz',echo=FALSE}
\begin{tikzpicture}
\tikzset{every node}=[font=\sffamily]
\node (v0) at (0,0) {E};
\node (v1) at (6,0)  {O};
\node[align=center] (v2) at (0,-2)  {A} ;
\draw [->] (v2) edge (v1);
\draw [->] (v2) edge (v0);
\draw [->] (v0) edge (v1);
\end{tikzpicture}
```

* The apparant relationship will differ from the causal one

```{r}
simulated_data <- tibble(
  A = rnorm(100),
  E = exp(-2 + A + rnorm(100,sd=0.2)),
  O = 10 + A + -4*E + rnorm(100)  # E reduces O
)
```


```{r, echo=FALSE}
simulated_data %>% 
  ggplot(aes(x=E, y=O)) + 
  geom_point() +
  geom_smooth(method='gam') +
  geom_abline(intercept = 10, slope=-4, col='red') +
  theme_bw() +
  labs(x='Exposure (E)', y="Outcome (O)")
```


# Simple DAG for the trastuzumab example

```{r,engine='tikz',echo=FALSE}
\begin{tikzpicture}
\tikzset{every node}=[font=\sffamily]
\node (v0) at (0,0) {exposure};
\node (v1) at (6,0)  {Alive at 1 year};
\node[align=center] (v2) at (0,-2)  {baseline\\disease severity} ;
\node (v3) at (-2,0) {CL};
\node (v4) at (-2,2)  {Weight};
\node (v5) at (0,2) {dose};
\draw [->] (v0) edge (v1);
\draw [->] (v2) edge (v1);
\draw [->] (v4) edge (v3);
\draw [->] (v2) edge (v3);
\draw [->] (v3) edge (v0);
\draw [->] (v5) edge (v0);
\end{tikzpicture}
```

__Weight:__ _baseline_ factor indirectly affecting exposure (through CL)

__Disease severity:__ _baseline_ factor directly affecting outcome and indirectly affecting exposure 

* Basline disease severity is counfounding the causal relationship between exposure and survival


# Why is this a problem?

We want to know the __causal__ effect of exposure on the outcome.

That is, if we change exposure how does the response change?

The data going into these analyses are essentially observational.

# Why is this a large molecule issue?

* For small molecules, baseline disease severity has much less of an impact on exposure

```{r,engine='tikz',echo=FALSE}
\begin{tikzpicture}
\tikzset{every node}=[font=\sffamily]
\node (v0) at (0,0) {exposure};
\node (v1) at (6,0)  {Alive at 1 year};
\node[align=center] (v2) at (0,-2)  {baseline\\disease severity} ;
\node (v3) at (-2,0) {CL};
\node (v4) at (-2,2)  {Weight};
\node (v5) at (0,2) {dose};
\draw [->] (v0) edge (v1);
\draw [->] (v2) edge (v1);
\draw [->] (v4) edge (v3);
\draw [->] (v3) edge (v0);
\draw [->] (v5) edge (v0);
\end{tikzpicture}
```

__Weight:__ _baseline_ factor indirectly affecting exposure (through CL)

__Disease severity:__ _baseline_ factor directly affecting outcome


# Why is this a 'one regimen' issue?

```{r,engine='tikz',echo=FALSE}
\begin{tikzpicture}
\tikzset{every node}=[font=\sffamily]
\node (v0) at (0,0) {exposure};
\node (v1) at (6,0)  {Alive at 1 year};
\node[align=center] (v2) at (0,-2)  {baseline\\disease severity} ;
\node (v3) at (-2,0) {CL};
\node (v4) at (-2,2)  {Weight};
\node (v5) at (0,2) {dose};
\draw [->] (v0) edge (v1);
\draw [->] (v2) edge (v1);
\draw [->] (v4) edge (v3);
\draw [->] (v2) edge (v3);
\draw [->] (v3) edge (v0);
\draw [->] (v5) edge (v0);
\end{tikzpicture}
```

Weight: baseline factor indirectly affecting exposure (through CL)
Disease severity: baseline factor directly affecting outcome and indirectly affecting exposure 


# Causal model with PD marker

```{r,engine='tikz',echo=FALSE}
\begin{tikzpicture}
\tikzset{every node}=[font=\sffamily]
\node (v0) at (0,0) {exposure};
\node (v1) at (6,0)  {Alive at 1 year};
\node[align=center] (v2) at (0,-2)  {baseline\\disease severity} ;
\node (v3) at (-2,0) {CL};
\node (v4) at (-2,2)  {Weight};
\node (v5) at (0,2) {dose};
\node (v6) at (3,0) {PD marker};
\draw [->] (v0) edge (v6);
\draw [->] (v2) edge (v1);
\draw [->] (v4) edge (v3);
\draw [->] (v2) edge (v3);
\draw [->] (v3) edge (v0);
\draw [->] (v5) edge (v0);
\draw [->] (v6) edge (v1);
\end{tikzpicture}
```

Weight: baseline factor indirectly affecting exposure (through CL)
Disease severity: baseline factor directly affecting outcome and indirectly affecting exposure 

# Causal model with PD marker and feedback

```{r,engine='tikz',echo=FALSE}
\begin{tikzpicture}
\tikzset{every node}=[font=\sffamily]
\node (v0) at (0,0) {exposure};
\node (v1) at (6,0)  {Alive at 1 year};
\node[align=center] (v2) at (0,-2)  {baseline\\disease severity} ;
\node (v3) at (-2,0) {CL};
\node (v4) at (-2,2)  {Weight};
\node (v5) at (0,2) {dose};
\node (v6) at (3,0) {PD marker};
\draw [->] (v0) edge (v6);
\draw [->] (v2) edge (v1);
\draw [->] (v4) edge (v3);
\draw [->] (v2) edge (v3);
\draw [->] (v3) edge (v0);
\draw [->] (v5) edge (v0);
\draw [->] (v6) edge (v1);
\draw [->, red] (v6) to [out=210,in=330] (v3);

\end{tikzpicture}
```


# Solutions

